VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HCL.
Professor Léa Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon I and Hospices Civils de Lyon, France commented:
"We are keen to support the submission of Volition's reimbursement dossier for its Nu.Q® Cancer assays so that we can introduce the test into routine, reimbursed clinical practice in France, through our extensive hospital network, for lung cancer management as soon as possible, hopefully later this year."
"We have worked closely with the Volition team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q® in the management of cancer patients. Our results indicate that measuring methylated nucleosome biomarker levels with the Nu.Q® test, at Non Small Cell Lung Cancer diagnosis, can provide valuable information about survival, progression-free survival and, crucially, enhance the identification of patients who may benefit from curative care." [1-3]
"Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring. This is a test we plan to use routinely."
Frederic Wuilque, Vice President, Global Products, added:
"With the active support of HCL, we are working towards the submission of our reimbursement dossier before the end of this quarter under the framework of the "Innovative Procedures Outside the Nomenclature" (RIHN-référentiel des actes innovants hors nomenclature). Once the dossier is classified as admissible, we understand that determination of eligibility for reimbursement coverage is mandated to take no more than five months."
"There are approximately 50,000 new lung cancer diagnoses in France each year with five-year prevalence of approximately 65,000 cases, thus the opportunity to provide help throughout patient management process is significant, in France alone[4].
From a commercial perspective, France is just the beginning; the Volition team is actively discussing Nu.Q® Cancer, not only with hospital networks in other countries but also potentially licensing the technology to third party collaborators."
Mr. Gael Forterre, Chief Commercial Officer, Volition concluded:
"We are honored to have the support of our long term collaborator, Hospices Civils de Lyon. Reimbursement is the next step on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives."
"Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. Once achieved, we anticipate the introduction into routine clinical use in France by the fourth quarter, 2026."
About Reimbursement
The Innovative Procedures Outside the Nomenclature (RIHN-référentiel des actes innovants hors nomenclature) framework allows for the early and temporary support of innovative procedures. This support is contingent upon the collection of data to facilitate the subsequent evaluation of these procedures by the French National Authority for Health (HAS), with a view to their integration into standard practice. Established by the Direction General for Healthcare (DGOS) as part of the development of innovation in healthcare, the RIHN provides a long-term support mechanism for innovative medical biology and anatomical pathology. Between 2021 and 2025, the DGOS led a reform to revitalize the RIHN and refocus it on innovation.
About Hospices Civils de Lyon (HCL)
The Hospices Civils de Lyon (HCL) are partners of the IHU SEPSIS (ex-PROMETHEUS). They constitute France's second-largest university hospital system (CHU). As a leading public healthcare institution, HCL encompasses 13 hospitals across the Lyon metropolitan area, covering all medical and surgical specialties. With over 23,000 professionals, including 5,000 physicians, HCL carries out missions in patient care, education, and research, in close collaboration with Université Claude Bernard Lyon 1 and numerous research institutes. As key contributors to medical innovation and healthcare organization in France, HCL provides high-quality care accessible to all patients. These capabilities are supported by state-of-the-art infrastructures in microbiology, molecular biology, and precision medicine, as well as active participation in clinical research and national surveillance networks.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, [email protected] +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
1. Grolleau E, et al. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules. 2023;13(8):1255. https://doi.org/10.3390/biom13081255
2. Couraud S, et al Baseline values of circulating nucleosomes in Lung Cancer: NUCLEO-LUNG study. ELCC 2024 Poster
3. Marie Piecyk et al, "H3K27Me3-nucleosome is a strong prognostic biomarker in Non-Small Cell Lung Cancer: interim results from the analysis of up to 832 patients at baseline" Poster 395 ELCC 2025
4. Global Cancer Observatory 2022 (accessed Jan 20, 2026)
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-the-preparation-of-reimbursement-submission-for-its-nuq-cancer-assays-302675011.html
SOURCE VolitionRx Limited